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Hormone Therapy and Breast Cancer
Menopause occurs naturally when the ovarian follicu-
lar pool is functionally exhausted, or it can also be
induced by surgical removal of both ovaries. The result-
ing hypoestrogenic state may adversely affect the estro-
gen target tissues, which include the brain, skeleton,
skin, and the cardiovascular and genitourinary systems
[1]. The reaction of target tissues to estrogen defi-
ciency, and the resultant frequency and severity of the
climacteric symptoms vary significantly among women.
These climacteric symptoms sometimes bother peri-
and/or postmenopausal women, resulting in severe
interference in their quality of life [2]. There are two
broad categories of menopausal hormone therapy (HT):
estrogen alone therapy (ET), and estrogen combined
with progestogen therapy (EPT) [1]. The goals of meno-
pausal hormone therapies are to (1) reduce symptoms
resulting from estrogen depletion, including hot flushes,
sleeplessness, lethargy, and depressed mood; (2) treat
urogenital atrophy and vaginal dryness; and (3) minimize
the risk of disorders that may be more frequent during
HT [1]. Although ET and EPT may improve a woman’s
quality of life, each woman has a unique risk profile
which might lead to more, or less, benefit from HT [1].
Most importantly, concerns have arisen regarding the
possible association of breast cancer and HT. An asso-
ciation between breast cancer and hormone use would
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SUMMARY
For decades, hormone therapy (HT) has been the mainstay for managing menopausal symptoms. However, the
prolonged use of either single estrogen therapy (ET) or a combination therapy of estrogen and progestogen
(EPT) might be associated with a slightly increased risk of breast cancer. Alternative therapies that are effective
in the prevention and/or treatment of menopause, having associated morbidities but no unwanted effects, are of
primary interest in clinical practice. Tibolone (Livial; NV Organon, Oss, The Netherlands) is structurally related
to 19-nortestosterone derivatives and is a new postmenopausal regimen with a unique pharmacological profile,
licensed for the relief of climacteric symptoms and the prevention of osteoporosis in postmenopausal women.
Tibolone exhibits weak estrogenic, progestogenic, and androgenic activities, which in theory might influence
the breast. The effect of tibolone on breast tissue, however, is obscure. The purpose of this study was to assess
the effects of tibolone on breast safety, and the collected data include preclinical models, clinical observation,
and epidemiologic study. Although in vitro studies showed conflicting results (with the majority being favorable
effects) regarding the effects of tibolone on breast cells, in vivo studies showed favorable effects of tibolone on
the breast in animal models. Similarly, an epidemiologic study indicated an increased risk of breast cancer when
tibolone was used to manage climacteric symptoms of postmenopausal women, but accumulated data obtained
from radiologic studies (mammography) showed a possible protective effect of tibolone on the breast. Taken
together, we conclude that tibolone, if not superior to conventional HT, may be more acceptable to clinicians
as a therapeutic drug option for use with symptomatic menopausal women. Only time will tell whether tibolone
will be the preferred option. [Taiwan J Obstet Gynecol 2007;46(2):121–126]
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be plausible because breast cancer incidence is increased
by hormonal factors such as early menarche and late
menopause [3]. In a 1997 reanalysis of 51 epidemiologic
studies, which included more than 90% of the world’s
literature on breast cancer and hormone use, breast
cancer risk increased by 2.3% per year of hormone use
(mostly estrogen use) compared with an increased risk of
2.8% per year for natural delay in the onset of menopause
[4], suggesting that HT does increase the risk of devel-
oping breast carcinoma and that this risk increases with
the increasing duration of HT use. A review of the 19
epidemiologic studies published after 1997 estimated
the average breast cancer risks to be 1.18 (95% confi-
dence interval, CI, 1.01–1.38) with current use of ET and
1.70 (95% CI, 1.36–2.17) with current use of EPT [5].
Data have accumulated in randomized clinical trials
involving more than 30,000 women and in epidemio-
logic studies involving more than 1.8 million women
[1,5]. With the use of ET, the average risk of invasive
breast cancer was 0.81 (95% CI, 0.63–1.03) in four
randomized trials involving 12,643 women [6–9]. With
the use of EPT, the average breast cancer risk was 1.24
(95% CI, 1.03–1.50) in four randomized trials involving
19,756 women [10–13]. The absolute effect of EPT in
the Women’s Health Initiative, and Heart and Estrogen/
Progestin Replacement Study trials added 8 and 17
cases per 10,000 women per year, respectively, to the
natural risk [12,14]. Breast cancer risk does not vary
significantly with different types of estrogen or prog-
estin preparations, with use of lower dosages or with
different routes of administration [5]. In six epidemio-
logic studies, including the Million Women Study [15],
the average relative risks with sequential and continu-
ous progestin regimens were 1.85 (95% CI, 1.72–1.99)
and 1.94 (95% CI, 1.78–2.11), respectively, a difference
that was not significant [5].
Although in the epidemiologic studies, the increased
breast cancer risk diminished soon after discontinuing
hormones and largely disappeared by 5 years after ces-
sation [5], the use of HT as a standard treatment applied
to all menopausal women will not meet the needs of
many individual women [1]. Health care providers
should therefore consider the relative balance between
the benefits and risks of treatment for each patient
before drawing conclusions or recommending HT.
Therefore, an alternative, such as tibolone that delivers
the beneficial but not the adverse side effects of steroid
hormones, would be clinically advantageous [16]. How-
ever, data from the Million Women Study suggested
that tibolone increases the risk of breast cancer [15]; but
when compared with conventional HT, tibolone seems
to be a relatively safe medication in terms of this risk [2].
Even with the increased risk to current users of 1.30
(1.21–1.40, p < 0.0001), 2.00 (1.88–2.12, p < 0.0001),
and 1.45 (1.25–1.68, p < 0.0001) for ET, EPT, and
tibolone, respectively, the magnitude of the associated
risk was substantially greater for EP than for other types
of HT (p < 0.0001) [15]. In order to understand the role
of tibolone therapy on the breast in postmenopausal
women, we reviewed recent studies addressing the
tibolone effect on the breast, including preclinical mod-
els, clinical observation, and epidemiologic study.
Tibolone
Tibolone (Livial®), which has been on the market since
1988, is a new postmenopausal regimen with a unique
pharmacologic profile, licensed for the relief of climac-
teric symptoms and the prevention of osteoporosis in
postmenopausal women [17–19]. Although tibolone is
frequently described as a HT product, recent research
has provided a clearer insight into the mechanism and
action of tibolone, which is significantly different from
those of conventional HT, such as ET and EPT [17].
The interesting clinical profile of tibolone was already
apparent in the first study into its effects on bone [20].
At that time, the estrogenic, progestogenic, and andro-
genic properties were known from classical bioassays,
but they could not fully explain the observed tissue-
selective effects, such as the estrogenic-like activity on
bone, vagina, and brain, and the non-stimulating effects
on the endometrium [20].
Tibolone lacks an aromatic A-ring and the 3-hydroxyl
substituent, normally required for agonist activity at
estrogen receptors (ERs), and yet its effects on brain,
bone, and vagina are estrogen-like. This indicated that
the estrogenic activity is due to metabolism into estro-
genic metabolites [17]. It was indeed subsequently found
that tibolone can be converted into two 3-hydroxy
metabolites (i.e. 3-α and 3-β hydroxy metabolites)
with estrogenic activity. Although the binding affinity
of these two estrogenic metabolites is low, the high
levels found in the circulation mean that a full biologic
response can be obtained [17], and the estrogenic activ-
ity is exerted in a tissue-selective manner [21–30]. In
addition, these two 3-hydroxy metabolites of tibolone
show selectivity for the classical ERα over the ERβ iso-
form [17]. Both hydroxy-metabolites have a half-life 
of approximately 7 hours, but circulatory levels of the
3α-hydroxy metabolite are about four times higher
than those of the 3β-hydroxy metabolite.
Tibolone has a 3-keto-5-10 steroid structure with
17α-ethinyl and 7α-methyl groups; it is very rapidly meta-
bolized to 3α- and 3β-hydroxy tibolone by hepatic and
intestinal 3α- and 3β-hydroxysteroid dehydrogenase
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(HSD) [17]. Tibolone is not a substrate for 3β-HSD
type I or type II, and the conversion is therefore most
likely due to 3β-HSD activity residing in 17β-HSD type II
[17]. A third metabolite, the 4-isomer of tibolone, is
formed directly from tibolone by 3β-HSD-isomerase,
for which the 3β-hydroxy metabolite is also a potential
substrate. The 4-isomer of tibolone activates the prog-
esterone and androgen receptors, but not the ER [31],
and has a higher affinity for progesterone receptor type
B than for type A.
The majority of the metabolites of tibolone (approx-
imately 80%) are in the inactive mono- and disulfated
forms, from which active estrogenic 3-hydroxy metabo-
lites may be continuously formed via the sulfatase
enzyme [32], the extent depending on the local enzyme
activity level. The 3α-hydroxy sulfated tibolone is, as
expected, the main sulfated metabolite [17]. Like the
parent compound, the 4-isomer is rapidly removed
from the circulation [17].
In vitro Studies of Tibolone on Breast
Epithelial Cells and Breast Cancer Cells
Tibolone and its metabolites have been shown to be very
potent inhibitors in the conversion of estrone sulfate
to estradiol in the hormone-dependent breast cancer
cell [27–29]. Studies have shown that the metabolites
of tibolone regulate the activity of local enzymes nor-
mally involved in the production of active estrogens in
the breast [30]. Tibolone has a different effect than con-
ventional HT at the level of the breast. It does not seem
to stimulate breast tissue and might have an inhibitory
effect on the growth of human breast tumor cells in
vitro [31], in addition to slowing down the prolifera-
tion rate and increasing differentiation and apoptosis
[27]. In normal breast cells, tibolone and its 4-isomer
significantly increased apoptosis, as indicated by flow
cytometry or morphologic analysis [32], because the
authors found that the proportion of cells showing apop-
totic features, such as blebbing, DNA fragmentation,
and nuclear destruction, was increased by tibolone and
its metabolites. To elucidate the possible mechanism,
the authors found that tibolone and its 4-isomer
induced 17β-HSD activity and strongly inhibited expres-
sion of Bcl-2 in normal breast cells [33]. The decrease in
Bcl-2 and slight decrease in Bcl-xl expression support
the effect of tibolone and the 4-metabolite on apop-
tosis, but these parameters were not influenced by the
two 3-hydroxy metabolites, thus suggesting that another
pathway may be involved [29]. The antiproliferative
effect of tibolone and its 4-metabolite, together with
their proapoptotic effect in breast tissue, suggests that
these substances may have beneficial effects on normal
and breast cancer cells [34].
In contrast, some studies showed conflicting results
[35]. In one study, tibolone was examined alone and in
the presence of 0.1 nM estradiol in the concentration
range of 0.001 µM to 1 µM. Tibolone led to significant
cell growth in the concentration range of 0.01 µM to
1 µM and was not able to inhibit estradiol-induced pro-
liferation at the concentrations of 0.01 µM and 0.1 µM
in the breast cancer cell experiments [35]. The authors
concluded that drawing a clinical consequence from
their experiments would result in not recommending the
use of tibolone in postmenopausal women at high risk
for breast cancer development until long-term controlled
clinical studies have been performed on the effect of
tibolone administration and breast cancer risk [35].
In vivo Studies of Tibolone on Breast
Epithelial Cells and Breast Cancer Cells
The well-known 7,12-dimethylbenz(a)anthracene
(DMBA)-rat model was used to test the effect of tibo-
lone, both in treatment and prophylactic protocols, on
tumor growth and initiation in rats. Tibolone inhibited
tumor growth at least as effectively as tamoxifen [30,
36]. In the prophylactic protocol, tibolone was extremely
efficacious in preventing tumor development. It was a
surprising observation that tibolone is converted mainly
to estrogenic metabolites. In ovariectomized monkeys,
2 years of treatment with tibolone did not stimulate
the breast, whilst a combination of conjugated equine
estrogens (CEE) plus medroxyprogesterone acetate
(MPA) resulted in a clear stimulation. The metabolism
of tibolone in this model monkey model was compara-
ble to that in postmenopausal women. Similarly, nor-
mal breast tissue in nude mice was not stimulated by
tibolone as shown by testing its effect on estrogenic-
sensitive parameters [36]. In the same model, trans-
planted MCF7 cells were also not stimulated by tibolone
[36]. Receptor studies using antagonistic transactiva-
tion assays ruled out the possibility of an antagonistic
effect of tibolone, or one of its metabolites, on any of
the steroid receptors [37]. Furthermore, the antitumor
effect of tibolone in the DMBA model was not sensitive
to flutamide, thus suggesting that it was not an andro-
genic effect [36]. In ovariectomized monkeys, it has been
shown that tibolone did not increase the proliferation
marker Ki67, whilst an increase was seen with CEE plus
MPA [38]. Valdivia et al even observed a significant
decrease in Ki67 and a concomitant increase in apopto-
sis in the biopsy specimens of postmenopausal women
treated with tibolone [39].
Taiwan J Obstet Gynecol • June 2007 • Vol 46 • No 2 123
Tibolone in Breast
Breast Tenderness in Women Treated
with Tibolone
In women, the lack of stimulating effects of tibolone
on the breast is illustrated by the absence of an increase
in breast tenderness, as seen with other HT [2,40].
Numerous studies have shown that breast pain is
increased in a small percentage of women treated with
tibolone; combined published data showed that 6% 
of women experience an increase and the same per-
centage showed a decrease [36]. In a recent placebo-
controlled trial conducted in 64 women who had
reported breast symptoms with a range of hormone re-
placement regimens, switching to tibolone or placebo
resulted in a significant reduction in breast tenderness
and mastalgia [41].
Mammographic Change in Women
Treated with Tibolone
An increase in mammographic density should be
regarded as an unwanted side effect of HT [42],
because increased breast density can impair the inter-
pretation of mammograms, thus increasing the failure
rate of breast cancer screening programs [36]. Tibolone
does not increase breast density and therefore does not
negatively affect mammographic screening for breast
cancer. Women on tibolone therefore require fewer
repeat mammograms. Valdivia et al [43] reported a
decrease in mammographic density compared with base-
line after 1 year of tibolone treatment, whereas treat-
ment with EPT induced an increase in breast density.
In a randomized, double-blind study comparing the
effects of tibolone and placebo in 20 women with
mastopathy, a reduction in breast density was observed
in 40% of the women receiving tibolone and 10% of
those given placebo [44]. A recently published article
on the long-term effects of tibolone on mammographic
density elaborated on tibolone’s unique effects on the
breast and suggested that tibolone seems to have a
minimal effect on mammographic density [21]. All of
the above suggest that tibolone has an advantage over
conventional HT in terms of breast cancer risk. Moreover,
tamoxifen is often used as adjuvant therapy and/or
preventive therapy for breast cancer. Unfortunately,
many women with breast cancer suffer vasomotor symp-
toms rather than risk recurrence with conventional HT.
In a small randomized controlled trial in women with
early breast cancer undergoing adjuvant tamoxifen treat-
ment, tibolone reduced hot flushes and night sweats
and improved quality of life compared with placebo
[45]. Dimitrakakis’ group designed an observational,
prospective, open, non-randomized study to assess the
safety and efficacy of tibolone for the treatment of 
climacteric symptoms in women who had a history 
of breast cancer which was treated with a complete 
(5-year) course of tamoxifen therapy [46]. The women
were followed up for a mean duration of 61 months
follow-up, and the authors found that tibolone was
effective in the treatment of climacteric symptoms and
was well tolerated in the tibolone group of 52 women.
The cancer recurrence rate in the tibolone group was
comparable to that of the untreated controls [46]. There-
fore, the authors concluded that the overall safety and
tolerance were similar to those of the general popula-
tion of postmenopausal women treated with tibolone
[46]. Moreover, tibolone has been shown to prevent
the increase in hot flushes in postmenopausal women
given tamoxifen following surgery for breast cancer
without untoward effects on the endometrium [47].
Clinically, tibolone does not act like an estrogen on the
endometrium (i.e. no hyperplasia), thus indicating that
sufficient progestogenic activity is exerted by tibolone
treatment. Progestogenic activity of tibolone is less
expressed, if at all, in the breast.
Potential Benefits of Tibolone in 
Treating Menopausal Syndrome
Although menopause is a natural course in women,
some women suffer from symptoms which significantly
affect their lives. In addition, circulating levels of estro-
gen are reduced in postmenopausal women, but the
breast tissue of postmenopausal women is able to syn-
thesize estrogens locally, which explains why the risk of
breast cancer is not minimized after menopause. In fact,
estradiol is the main factor supporting the growth and
evolution of breast cancers, and one of the pathways
involved in the transformation of estradiol is the sulfa-
tase pathway, which transforms estrone sulfate to estra-
diol [27], especially after menopause.
Numerous clinical studies have shown that tibolone
has beneficial effects in relation to climacteric symp-
toms and vaginal atrophy in postmenopausal women;
relief from climacteric symptoms develops within 3–5
weeks, and the maximum effect is usually seen by 
3 months [48]. In addition, tibolone shows beneficial
effects on mood and sexual well-being [49]. The results
of this observation demonstrate a similar positive effect
in improving insomnia, libido, and mood instability, and
most importantly, there was a high rate of continuous
use of tibolone. Moreover, the low dosage (1.25 mg/
day) seemed to be effective for women with climacteric
symptoms. In this observation study, seven women were
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reported to be satisfied with this low dosage treatment,
which is in agreement with a previous report showing
that tibolone induced a decrease in the frequency and
intensity of climacteric symptoms, leading to statistically
significant differences compared to placebo, for dose
levels of 1.25 mg and higher [50].
Concerning irregular vaginal spotting and/or possi-
ble unwanted pathologic changes to the endometrium,
tibolone therapy is reported to have high rates of amen-
orrhea after 10 years, with minimal evidence of adverse
effects on endometrial pathology [51]. In our previous
study, we also found that irregular bleeding episodes
were markedly decreased during and at the end of
treatment [2].
In terms of biochemical changes in the blood,
tibolone is reported to lower lipoprotein(a), fibrino-
gen, and plasminogen activator inhibitor-1 levels and
to improve glucose tolerance, insulin sensitivity, and
endothelial function. However, it also lowers high-
density lipoprotein cholesterol by more than 20% [52].
Therefore, the long-term impact of tibolone on the risk
of coronary heart disease is not known and needs to
be studied [52].
With the beneficial effect of preventing and/or treat-
ing osteoporosis, tibolone prevents bone loss and has
been shown to increase the bone mineral density in
early and late postmenopausal women [53].
Conclusion
Although in vitro studies showed conflicting results
regarding the effects of tibolone on breast cells, in vivo
studies showed a protective effect of tibolone on the
breast in animal models. Although epidemiologic stud-
ies show an increase in the risk of breast cancer among
women treated with tibolone, accumulation of data
obtained from radiologic studies presents promising
results. Since tibolone, as a selective tissue estrogenic
activity regulator [50], is easy to use, only a single
tablet containing 2.5 mg of tibolone is needed every
day [2]. Tibolone, if not superior to conventional HT,
may be more acceptable to clinicians as a therapeutic
drug option for symptomatic menopausal women. Time
will tell.
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